Search results
Results from the WOW.Com Content Network
Glipizide, sold under the brand name Glucotrol among others, is an anti-diabetic medication of the sulfonylurea class used to treat type 2 diabetes. [1] [2] It is used together with a diabetic diet and exercise. [1] [2] It is not indicated for use by itself in type 1 diabetes. [1] [2] It is taken by mouth.
Use during pregnancy and breastfeeding is not recommended. [3] It works predominantly by increasing the amount of insulin released from the pancreas. [1] It is classified as a second-generation sulfonylurea. [4] Glimepiride was patented in 1979 and approved for medical use in 1995. [5] It is available as a generic medication. [2]
Elimination half-life: 7 days: Duration of action: 63.6 h: Excretion: ... Formula: C 187 H 291 N 45 O 59: ... Semaglutide's half-life in the blood is about seven days ...
Whether use in pregnancy or breastfeeding is safe is unclear. [10] It is in the dipeptidyl peptidase-4 (DPP-4) inhibitor class and works by increasing the production of insulin and decreasing the production of glucagon by the pancreas. [8] Sitagliptin was developed by Merck & Co. and approved for medical use in the United States in 2006. [8]
It is generally not recommended during pregnancy but can be used during breastfeeding. [3] It is in the sulfonylureas class of medications and works by increasing the release of insulin from the pancreas. [1] Glibenclamide was discovered in 1969 and approved for medical use in the United States in 1984. [4] [1] It is available as a generic ...
Elimination half-life: 4.5 to 6.5 hours: Excretion: Renal: ... Formula: C 12 H 18 N 2 O 3 S: Molar mass: ... It generally has a short duration of action due to its ...
Tolazemide synthesis: [1] U.S. patent 3,063,903 GB 887886 DE 1196200 para-Toluenesulfonamide is converted to its carbamate with ethyl chloroformate in the presence of a base.
The elimination half-life of MPA via oral administration has been reported as both 11.6 to 16.6 hours [6] and 33 hours, [4] whereas the elimination half-lives with intramuscular and subcutaneous injection of microcrystalline MPA in aqueous suspension are 50 and 40 days, respectively.